What is Novo Nordisk A/s share price today?

Novo Nordisk A/s (NVO) share price today is {{live_price}}.

Can Indians buy Novo Nordisk A/s shares?

Yes, Indians can invest in the Novo Nordisk A/s (NVO) from India. With INDmoney, you can buy Novo Nordisk A/s at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Novo Nordisk A/s at zero transaction cost.

How can I buy Novo Nordisk A/s shares from India?

It is very easy to buy Novo Nordisk A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Novo Nordisk A/s be purchased?

Yes, you can buy fractional shares of Novo Nordisk A/s with INDmoney app.

What are the documents required to start investing in Novo Nordisk A/s stocks?

To start investing in Novo Nordisk A/s, You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Novo Nordisk A/s

Today’s highest price of Novo Nordisk A/s (NVO) is {{1_rba_end}}. Today’s lowest price of Novo Nordisk A/s (NVO) is {{1_rba_st}}.

What is today's market capitalisation of Novo Nordisk A/s

Today's market capitalisation of Novo Nordisk A/s NVO is 529.8B

What is the 52 Week High and Low Range of Novo Nordisk A/s

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Novo Nordisk A/s is down from its 52 Week High?

Novo Nordisk A/s (NVO) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Novo Nordisk A/s is up from its 52 Week low?

Novo Nordisk A/s (NVO) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Novo Nordisk A/s?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Novo Nordisk A/s

Mr. Lars Fruergaard Jorgensen is the current Chief Executive Officer (CEO) of Novo Nordisk A/s.

Home>
US Stocks>
Novo Nordisk A/s

Novo Nordisk A/s (NVO)

$117.4

-0.69

(-0.58%)▲

Live

Novo Nordisk A/S is a global healthcare company that specializes in the development, production, and marketing of pharmaceutical products.

Performance

$116.88
$117.84
$117.40
0.44%
Downside
Day's Volatility :0.81%
Upside
0.37%
$92.94
$148.15
$117.40
20.83%
Downside
52 Weeks Volatility :37.27%
Upside
20.76%

Returns

Period	Novo Nordisk A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	-11.33%	3.6%	0.0%
6 Months	-5.72%	10.2%	0.0%
1 Year	21.59%	19.6%	0.0%
3 Years	126.2%	16.8%	-23.0%

Highlights

Market Capitalization	529.8B
Book Value	$25.24
Dividend Share	9.9
Dividend Yield	1.23%
Earnings Per Share (EPS)	2.94
PE Ratio	40.21
PEG Ratio	1.81
Wall Street Target Price	142.24

Profit Margin	34.84%
Operating Margin TTM	46.48%

Return On Assets TTM	22.8%
Return On Equity TTM	88.57%

Revenue TTM	258.0B
Revenue Per Share TTM	57.8
Quarterly Revenue Growth YOY	25.3%
Gross Profit TTM	148.5B
EBITDA	126.6B
Diluted Eps TTM	2.94
Quarterly Earnings Growth YOY	0.04

EPS Estimate Current Year	3.36
EPS Estimate Next Year	4.17
EPS Estimate Current Quarter	0.7
EPS Estimate Next Quarter	0.89

Analyst Recommendation

Buy

62%Buy

31%Hold

6%Sell

Based on 32 Wall street analysts offering stock ratings for Novo Nordisk A/s(by analysts ranked 0 to 5 stars)

Based on 32 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 21.16%

Current $117.40

Target $142.24

Company Financials

	FY18	Y/Y Change
Revenue	17.0B	↑ 0.12%
Net Income	5.9B	↑ 1.31%
Net Profit Margin	34.54%	↑ 0.4%

	FY19	Y/Y Change
Revenue	18.1B	↑ 9.11%
Net Income	5.8B	↑ 0.84%
Net Profit Margin	31.92%	↓ 2.62%

	FY20	Y/Y Change
Revenue	20.7B	↑ 4.04%
Net Income	6.9B	↑ 8.18%
Net Profit Margin	33.19%	↑ 1.27%

	FY21	Y/Y Change
Revenue	21.4B	↑ 10.91%
Net Income	7.3B	↑ 13.33%
Net Profit Margin	33.92%	↑ 0.73%

	FY22	Y/Y Change
Revenue	25.2B	↑ 25.68%
Net Income	7.9B	↑ 16.27%
Net Profit Margin	31.38%	↓ 2.54%

	FY23	Y/Y Change
Revenue	34.0B	↑ 31.26%
Net Income	12.3B	↑ 50.71%
Net Profit Margin	36.03%	↑ 4.65%

	Q1 FY23	Q/Q Change
Revenue	7.7B	↑ 10.97%
Net Income	2.8B	↑ 45.78%
Net Profit Margin	37.13%	↑ 8.87%

	Q2 FY23	Q/Q Change
Revenue	7.9B	↑ 1.75%
Net Income	2.8B	↓ 1.95%
Net Profit Margin	35.78%	↓ 1.35%

	Q3 FY23	Q/Q Change
Revenue	8.4B	↑ 8.16%
Net Income	3.2B	↑ 15.7%
Net Profit Margin	38.27%	↑ 2.49%

	Q4 FY23	Q/Q Change
Revenue	9.6B	↑ 12.14%
Net Income	3.2B	↓ 2.29%
Net Profit Margin	33.35%	↓ 4.92%

	Q1 FY24	Q/Q Change
Revenue	9.5B	↓ 0.78%
Net Income	3.7B	↑ 15.68%
Net Profit Margin	38.88%	↑ 5.53%

	Q2 FY24	Q/Q Change
Revenue	9.8B	↑ 4.15%
Net Income	2.9B	↓ 21.08%
Net Profit Margin	29.46%	↓ 9.42%

	FY18	Y/Y Change
Total Assets	16.9B	↑ 8.22%
Total Liabilities	9.0B	↑ 12.16%

	FY19	Y/Y Change
Total Assets	18.7B	↑ 13.4%
Total Liabilities	10.1B	↑ 15.42%

	FY20	Y/Y Change
Total Assets	23.7B	↑ 15.37%
Total Liabilities	13.3B	↑ 19.96%

	FY21	Y/Y Change
Total Assets	29.6B	↑ 34.22%
Total Liabilities	18.8B	↑ 51.67%

	FY22	Y/Y Change
Total Assets	34.3B	↑ 24.03%
Total Liabilities	22.4B	↑ 27.48%

	FY23	Y/Y Change
Total Assets	46.1B	↑ 30.35%
Total Liabilities	30.5B	↑ 31.79%

	Q1 FY23	Q/Q Change
Total Assets	35.9B	↑ 3.63%
Total Liabilities	24.5B	↑ 7.85%

	Q2 FY23	Q/Q Change
Total Assets	40.9B	↑ 12.29%
Total Liabilities	27.7B	↑ 11.83%

	Q3 FY23	Q/Q Change
Total Assets	43.0B	↑ 6.89%
Total Liabilities	29.7B	↑ 8.84%

	Q4 FY23	Q/Q Change
Total Assets	46.1B	↑ 4.79%
Total Liabilities	30.5B	↑ 0.39%

	Q1 FY24	Q/Q Change
Total Assets	43.6B	↓ 4.95%
Total Liabilities	29.2B	↓ 3.81%

	Q2 FY24	Q/Q Change
Total Assets	53.3B	↑ 23.57%
Total Liabilities	37.1B	↑ 28.42%

	FY18	Y/Y Change
Operating Cash Flow	6.8B	↑ 8.38%
Investing Cash Flow	-1.8B	↑ 83.84%
Financing Cash Flow	-5.3B	↓ 3.27%

	FY19	Y/Y Change
Operating Cash Flow	7.0B	↑ 4.85%
Investing Cash Flow	-1.7B	↓ 4.73%
Financing Cash Flow	-5.3B	↑ 2.79%

	FY20	Y/Y Change
Operating Cash Flow	8.5B	↑ 11.05%
Investing Cash Flow	-3.7B	↑ 94.94%
Financing Cash Flow	-5.3B	↓ 9.13%

	FY21	Y/Y Change
Operating Cash Flow	8.4B	↑ 5.87%
Investing Cash Flow	-4.8B	↑ 40.87%
Financing Cash Flow	-3.9B	↓ 20.94%

	FY22	Y/Y Change
Operating Cash Flow	11.2B	↑ 43.43%
Investing Cash Flow	-3.5B	↓ 21.16%
Financing Cash Flow	-7.4B	↑ 103.18%

	Q1 FY23	Q/Q Change
Operating Cash Flow	4.3B	↑ 319.86%
Investing Cash Flow	-955.4M	↓ 73.32%
Financing Cash Flow	-3.0B	↑ 168.92%

	Q2 FY23	Q/Q Change
Operating Cash Flow	4.2B	↓ 4.15%
Investing Cash Flow	-2.3B	↑ 139.69%
Financing Cash Flow	-1.8B	↓ 38.95%

	Q3 FY23	Q/Q Change
Operating Cash Flow	5.9B	↑ 43.35%
Investing Cash Flow	-4.2B	↑ 83.12%
Financing Cash Flow	-2.8B	↑ 57.53%

Technicals Summary

Sell

Neutral

Buy

Novo Nordisk A/s is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novo Nordisk A/s	-4.54%	-5.72%	21.59%	126.2%	349.01%
Regeneron Pharmaceuticals, Inc.	-9.28%	10.06%	24.53%	74.0%	232.45%
Alnylam Pharmaceuticals, Inc.	8.87%	102.98%	82.67%	44.83%	241.09%
Vertex Pharmaceuticals Incorporated	5.0%	20.77%	31.37%	158.16%	163.17%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novo Nordisk A/s	40.21	40.21	1.81	3.36	0.89	0.23	0.01	25.24
Regeneron Pharmaceuticals, Inc.	26.41	26.41	1.37	44.9	0.17	0.08	NA	261.41
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-2.42	-15.01	0.02	NA	-0.02
Vertex Pharmaceuticals Incorporated	32.84	NA	0.59	0.18	-0.03	0.13	NA	57.26

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novo Nordisk A/s	Buy	$529.8B	349.01%	40.21	34.84%
Regeneron Pharmaceuticals, Inc.	Buy	$110.0B	232.45%	26.41	32.04%
Alnylam Pharmaceuticals, Inc.	Buy	$38.1B	241.09%	NA	-3.11%
Vertex Pharmaceuticals Incorporated	Buy	$128.7B	163.17%	32.84	-4.74%

Insights on Novo Nordisk A/s

Increasing Revenue
Revenue is up for the last 2 quarters, 65.34B → 68.06B (in $), with an average increase of 4.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 25.40B → 20.05B (in $), with an average decrease of 21.1% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 60.3%

Institutional Holdings

Jennison Associates LLC
0.48%
FMR Inc
0.44%
Morgan Stanley - Brokerage Accounts
0.33%
Bank of America Corp
0.32%
Fisher Asset Management, LLC
0.30%
Fayez Sarofim & Company
0.28%

Corporate Announcements

Novo Nordisk A/s Dividends March,2024
In the quarter ending March,2024. Novo Nordisk A/s has declared dividend of $0.93
Read More

Organization	Novo Nordisk A/s
Employees	69260
CEO	Mr. Lars Fruergaard Jorgensen
Industry	Health Technology

Novo Nordisk A/s (NVO)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Increasing Revenue

Decreasing Net Profit

Vs ALNY

Institutional Holdings

Corporate Announcements

Novo Nordisk A/s Dividends March,2024

Company Information

Discover More

FAQs